A Systematic Review of the Epidemiology and Disease Burden of Congenital and Immune-Mediated Thrombotic Thrombocytopenic Purpura

被引:3
作者
Du, Ping [1 ]
Cristarella, Tiffany [2 ]
Goyer, Camille [2 ]
Moride, Yola [2 ,3 ]
机构
[1] Takeda Dev Ctr Amer Inc, Global Evidence & Outcomes, Cambridge, MA 02142 USA
[2] YolaRX Consultants Inc, Montreal, PQ, Canada
[3] Rutgers State Univ, Ctr Pharmacoepidemiol & Treatment Sci, New Brunswick, NJ USA
来源
JOURNAL OF BLOOD MEDICINE | 2024年 / 15卷
关键词
thrombotic thrombocytopenic purpura; epidemiology; burden of illness; disease management; patient-reported outcomes; ADAMTS13; THERAPEUTIC PLASMA-EXCHANGE; FRENCH NATIONAL REGISTRY; SEVERE ADAMTS13 DEFICIENCY; SINGLE-CENTER EXPERIENCE; CLINICAL CHARACTERISTICS; HIGH PREVALENCE; ADULT PATIENTS; OUTCOMES; TTP; MANAGEMENT;
D O I
10.2147/JBM.S464365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Congenital (cTTP) and immune-mediated (iTTP) thrombotic thrombocytopenic purpura are serious and rare clotting disorders resulting from a deficiency in the ADAMTS13 enzyme. A systematic review was conducted using the Ovid (R) MEDLINE & Embase databases to synthesize the epidemiology and burden of cTTP and iTTP worldwide (from January 1, 2010, to February 6, 2020, with an update that covered the period January 1, 2020-February 11, 2022). Outcomes of interest were incidence and prevalence of TTP, incidence of acute episodes, mortality, burden of illness (eg complications, healthcare utilization, patient-reported outcomes) and disease management. A total of 221 eligible observational studies were included. The incidence rate of acute episodes ranged from 0.19-0.35 person-years in adult patients with cTTP, and 1.81-3.93 per million persons per year for iTTP in the general population. Triggers of acute episodes were similar for cTTP and iTTP, with pregnancy and infection the most commonly observed. Exacerbation in patients with iTTP varied widely, ranging from 2.4-63.1%. All-cause mortality was observed in 0-13.4% of patients with cTTP, across studies and follow-up periods, and in 1.1% (median follow-up: 0.4 years) to 18.8% (1 year) of patients with iTTP during acute episodes. Cardiovascular, renal, and neurological disease were common complications. TTP also led to work disturbances, feelings of anxiety and depression, and general activity impairment. TTP treatment regimens used were generally reflective of current treatment guidelines. The evidence identified describes a high patient burden, highlighting the need for effective treatment regimens leading to improvements in outcomes. Considerable evidence gaps exist, particularly for disease epidemiology, patient-reported outcomes, costs of disease management, and associated healthcare resource utilization. This review may help increase disease awareness and highlights the need for additional real-world studies, particularly in geographical regions outside the United States and Western Europe.
引用
收藏
页码:363 / 386
页数:24
相关论文
共 50 条
  • [41] Immature platelet dynamics in management of protracted response to therapy of a young pediatric patient with immune-mediated thrombotic thrombocytopenic purpura
    Maitta, Robert W.
    Reeves, Hollie M.
    Downes, Katharine A.
    He, Xiangrong
    Hackney, Lisa R.
    Ahuja, Sanjay P.
    THROMBOSIS RESEARCH, 2023, 228 : 145 - 147
  • [42] A comparative study of anti-ADAMTS-13 antibody dynamics in immune-mediated thrombotic thrombocytopenic purpura
    Cozzi, Maria Rita
    Del Ben, Fabio
    Corso, Chiara
    Steffan, Agostino
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (05)
  • [43] Predictors of acute ischemic cerebral lesions in immune-mediated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
    Neuman, Lisa
    Joseph, Adrien
    Bouzid, Raida
    Lescroart, Mickael
    Mariotte, Eric
    Ederhy, Stephane
    Tuffet, Sophie
    Baudel, Jean-Luc
    Benhamou, Ygal
    Galicier, Lionel
    Grange, Steven
    Provot, Francois
    Neel, Antoine
    Pene, Frederic
    Delmas, Yahsou
    Presne, Claire
    Poullin, Pascale
    Wynckel, Alain
    Perez, Pierre
    Barbet, Christelle
    Halimi, Jean-Michel
    Chatelet, Val'rie
    Rebibou, Jean-Michel
    Ojeda-Uribe, Mario
    Vigneau, C'cile
    Mesnard, Laurent
    Veyradier, AgnSs
    Azoulay, Elie
    Coppo, Paul
    Chabriat, Hugues
    Prospective Multictr MATRISK study, Prospective Multictr M. A. T. R. I. S. K. study
    JOURNAL OF NEUROLOGY, 2023, 270 (10) : 5023 - 5033
  • [44] Real-World Data Analysis of Patients Affected by Immune-Mediated Thrombotic Thrombocytopenic Purpura in Italy
    Angelucci, Emanuele
    Artoni, Andrea
    Fianchi, Luana
    Dovizio, Melania
    Iacolare, Biagio
    Saragoni, Stefania
    Esposti, Luca Degli
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (05)
  • [45] Predictors of acute ischemic cerebral lesions in immune-mediated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
    Lisa Neuman
    Adrien Joseph
    Raïda Bouzid
    Mickael Lescroart
    Eric Mariotte
    Stéphane Ederhy
    Sophie Tuffet
    Jean-Luc Baudel
    Ygal Benhamou
    Lionel Galicier
    Steven Grangé
    François Provôt
    Antoine Neel
    Frédéric Pène
    Yahsou Delmas
    Claire Presne
    Pascale Poullin
    Alain Wynckel
    Pierre Perez
    Christelle Barbet
    Jean-Michel Halimi
    Valérie Chatelet
    Jean-Michel Rebibou
    Mario Ojeda-Uribe
    Cécile Vigneau
    Laurent Mesnard
    Agnès Veyradier
    Elie Azoulay
    Paul Coppo
    Hugues Chabriat
    Journal of Neurology, 2023, 270 : 5023 - 5033
  • [46] CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA IN CHILDREN
    Shutova, A. D.
    Kalinina, I. I.
    Suntsova, E., V
    Roikina, E., V
    Galstyon, G. M.
    Smetanina, N. S.
    Maschan, A. A.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2023, 68 (04): : 443 - 455
  • [47] Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura
    Roose, Elien
    Vidarsson, Gestur
    Kangro, Kadri
    Verhagen, Onno J. H. M.
    Mancini, Ilaria
    Desender, Linda
    Pareyn, Inge
    Vandeputte, Nele
    Vandenbulcke, Aline
    Vendramin, Chiara
    Schelpe, An-Sofie
    Voorberg, Jan
    Azerad, Marie-Agnes
    Gilardin, Laurent
    Scully, Marie
    Dierickx, Daan
    Deckmyn, Hans
    De Meyer, Simon F.
    Peyvandi, Flora
    Vanhoorelbeke, Karen
    THROMBOSIS AND HAEMOSTASIS, 2018, 118 (10) : 1729 - 1742
  • [48] Immune Thrombotic Thrombocytopenic Purpura in Elderly Patients: The Roles of PLASMIC and French Scores
    Baysal, Mehmet
    Hindilerden, Fehmi
    Umit, Elif Gulsum
    Demir, Ahmet Muzaffer
    Karadag, Fatma Keklik
    Saydam, Guray
    Akpinar, Seval
    Turgut, Burhan
    Ozkocaman, Vildan
    Ozkalemkas, Fahir
    Ciftciler, Rafiye
    Ozlu, Can
    Demircioglu, Sinan
    Ipek, Yildiz
    Kucukkaya, Reyhan Diz
    TURKISH JOURNAL OF HEMATOLOGY, 2023, 40 (04) : 251 - 257
  • [49] Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature
    Elliott, Mischelle A.
    Heit, John A.
    Pruthi, Rajiv K.
    Gastineau, Dennis A.
    Winters, Jeffrey L.
    Hook, C. Christopher
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 83 (04) : 365 - 372
  • [50] Clinical features and neurological outcomes in pediatric immune-mediated thrombotic thrombocytopenic purpura: A report from a large pediatric hematology center
    Graciaa, Sara
    Adeagbo, Segun
    Fong, Grace
    Rollins, Margo
    McElfresh, Patricia
    Zerra, Patricia E.
    Bennett, Carolyn
    Josephson, Cassandra D.
    Briones, Michael
    Fasano, Ross M.
    Chonat, Satheesh
    PEDIATRIC BLOOD & CANCER, 2022, 69 (12)